Additionally, our in vivo studies in orthotopic glioma‐bearing mice models demonstrated that the administration of S1P/JS‐K/TMZ/Lipo improved the immune response of the brain glioma, including an increase in DAMPs released from tumor cells and an increase in infiltration of mature dendritic cells (CD11c+MHC‐II+) and cytotoxic T cells (CD3+CD8+), accompanied by an improved survival rate of S1P/JS‐K/TMZ/Lipo‐treated animals compared to PBS‐treated or control nanoliposome–treated animals. This evidence concerns the gene CD8A and central nervous system cancer.